
William J. Polvino is leaving Veloxis after more than six years in charge of the biotech company as its Chief Executive Officer. He will be replaced at the helm by Craig A. Collard, who joins from a CEO position at BioMarck Pharmaceuticals, with immediate effect, the company says in a stock market release.
In his time in charge of the Danish company, William Polvino has helped develop and win approval for Envarsus, a drug used to prevent organ rejection in patients who undergo kidney transplants. His departure is announced on the same week when the drug was launched on the US market.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app